Table 4.

Summary of the results obtained using Box-Behnken design

Batches	Y1	Y2	Y3	Y4	Particle size (nm)	PDI	Zeta potential (mV)	%EE
BB-1	90	1.5	5	10	110.48±4.72	0.224±0.031	−6.32±0.46	62.43±2.63
BB-2	110	1.5	15	5	109.61±3.76	0.262±0.028	−10.86±0.51	81.91±3.41
BB-3	90	1.5	10	15	143.48±6.02	0.339±0.035	−8.61±0.47	58.03±2.62
BB-4	130	1.5	10	5	195.50±6.83	0.336±0.027	−4.06±0.24	87.45±2.48
BB-5	110	1.5	10	10	110.03±3.09	0.218±0.031	−6.60±0.33	79.92±4.01
BB-6	110	1.0	10	15	526.14±4.46	0.651±0.048	−9.20±0.58	79.34±3.85
BB-7	110	2.0	10	15	108.52±3.68	0.215±0.032	−7.83±0.46	57.43±3.36
BB-8	130	2.0	10	10	123.53±4.32	0.209±0.019	−8.52±0.32	72.31±2.34
BB-9	110	2.0	15	10	110.01±2.59	0.211±0.039	−11.50±0.52	68.06±3.75
BB-10	110	1.5	15	15	134.28±2.48	0.286±0.045	−10.50±0.48	68.74±2.56
BB-11	110	2.0	10	5	106.32±3.65	0.213±0.036	−8.86±0.59	78.91±3.33
BB-12	130	1.5	10	15	202.46±4.24	0.325±0.028	−7.51±0.42	82.64±4.21
BB-13	110	1.5	10	10	110.02±2.76	0.218±0.034	−6.62±0.33	79.92±3.76
BB-14	130	1.5	5	10	188.92±4.93	0.358±0.038	−4.46±0.27	83.21±2.64
BB-15	110	2.0	5	10	107.89±3.52	0.208±0.040	−5.01±0.38	67.58±3.32
BB-16	110	1.5	5	5	109.15±4.26	0.216±0.046	−5.06±0.42	83.02±4.27
BB-17	110	1.0	15	10	492.47±10.43	0.489±0.076	−10.65±0.73	84.51±4.35
BB-18	110	1.5	10	10	110.06±4.02	0.218±0.034	−6.61±0.47	79.92±4.84
BB-19	110	1.5	5	15	108.66±3.54	0.203±0.035	−4.33±0.36	69.63±2.66
BB-20	90	1.0	10	10	163.67±5.38	0.307±0.064	−6.50±0.35	76.52±3.46
BB-21	90	1.5	10	5	107.51±2.76	0.245±0.028	−8.50±0.49	73.68±2.57
BB-22	130	1.5	15	10	198.84±4.46	0.263±0.053	−9.98±0.62	83.34±3.39
BB-23	110	1.0	10	5	315.60±7.36	0.385±0.032	−7.84±0.59	84.55±4.68
BB-24	130	1.0	10	10	708.32±12.84	0.668±0.047	−8.50±0.61	86.20±2.95
BB-25	110	1.0	5	10	408.68±6.34	0.502±0.062	−4.32±0.36	85.57±3.43
BB-26	90	2.0	10	10	103.48±3.65	0.201±0.027	−8.86±0.53	48.23±5.32
BB-27	90	1.5	15	10	109.52±3.98	0.223±0.023	−9.60±0.72	58.91±2.02

Y1= Total lipid (mg), Y2= Surfactant concentration (%), Y3= Oil (%), Y4= Drug (%),